Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 19, Issue 11, Pages 1233-1239Publisher
WILEY
DOI: 10.1111/j.1440-1746.2003.03325.x
Keywords
chronic hepatitis; interferon; pegylated; ribavirin; therapy
Categories
Ask authors/readers for more resources
Hepatitis C virus (HCV) genotype 4 is predominantly found in the Middle East and North Africa. Because most of the large randomized controlled trials of antiviral therapy for chronic hepatitis C were conducted in North America and Europe, little is known about management of patients with this particular genotype. Based on the available data, sustained virological response rates to interferon-based therapies appear to be intermediate between the relatively resistant HCV genotype I and the readily responsive genotypes 2 and 3. Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed. (C) 2004 Blackwell Publishing Asia Pry Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available